212 related articles for article (PubMed ID: 30304034)
61. The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy.
Wang P; Mao B; Luo W; Wei B; Jiang W; Liu D; Song L; Ji G; Yang Z; Lai YQ; Yuan Z
Basic Res Cardiol; 2014; 109(5):435. PubMed ID: 25168380
[TBL] [Abstract][Full Text] [Related]
62. The Hippo component YAP localizes in the nucleus of human papilloma virus positive oropharyngeal squamous cell carcinoma.
Alzahrani F; Clattenburg L; Muruganandan S; Bullock M; MacIsaac K; Wigerius M; Williams BA; Graham ME; Rigby MH; Trites JR; Taylor SM; Sinal CJ; Fawcett JP; Hart RD
J Otolaryngol Head Neck Surg; 2017 Feb; 46(1):15. PubMed ID: 28222762
[TBL] [Abstract][Full Text] [Related]
63. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
[TBL] [Abstract][Full Text] [Related]
64. The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number.
Lavado A; Park JY; Paré J; Finkelstein D; Pan H; Xu B; Fan Y; Kumar RP; Neale G; Kwak YD; McKinnon PJ; Johnson RL; Cao X
Dev Cell; 2018 Dec; 47(5):576-591.e8. PubMed ID: 30523785
[TBL] [Abstract][Full Text] [Related]
65. YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29.
Tumaneng K; Schlegelmilch K; Russell RC; Yimlamai D; Basnet H; Mahadevan N; Fitamant J; Bardeesy N; Camargo FD; Guan KL
Nat Cell Biol; 2012 Dec; 14(12):1322-9. PubMed ID: 23143395
[TBL] [Abstract][Full Text] [Related]
66. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
Wang Z; Wu Y; Wang H; Zhang Y; Mei L; Fang X; Zhang X; Zhang F; Chen H; Liu Y; Jiang Y; Sun S; Zheng Y; Li N; Huang L
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):E89-98. PubMed ID: 24367099
[TBL] [Abstract][Full Text] [Related]
67. Overexpression of the YAP1 oncogene in clear cell renal cell carcinoma is associated with poor outcome.
Rybarczyk A; Klacz J; Wronska A; Matuszewski M; Kmiec Z; Wierzbicki PM
Oncol Rep; 2017 Jul; 38(1):427-439. PubMed ID: 28504812
[TBL] [Abstract][Full Text] [Related]
68. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
69. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
[TBL] [Abstract][Full Text] [Related]
70. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
71. MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms.
Alexander MS; Casar JC; Motohashi N; Vieira NM; Eisenberg I; Marshall JL; Gasperini MJ; Lek A; Myers JA; Estrella EA; Kang PB; Shapiro F; Rahimov F; Kawahara G; Widrick JJ; Kunkel LM
J Clin Invest; 2014 Jun; 124(6):2651-67. PubMed ID: 24789910
[TBL] [Abstract][Full Text] [Related]
72. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP).
Oka T; Mazack V; Sudol M
J Biol Chem; 2008 Oct; 283(41):27534-27546. PubMed ID: 18640976
[TBL] [Abstract][Full Text] [Related]
73. Two faces of Hippo: activate or suppress the Hippo pathway in cancer.
Cao J; Huang W
Anticancer Drugs; 2017 Nov; 28(10):1079-1085. PubMed ID: 28926422
[TBL] [Abstract][Full Text] [Related]
74. MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.
Alam M; Bouillez A; Tagde A; Ahmad R; Rajabi H; Maeda T; Hiraki M; Suzuki Y; Kufe D
Mol Cancer Res; 2016 Dec; 14(12):1266-1276. PubMed ID: 27658423
[TBL] [Abstract][Full Text] [Related]
75. Chronic stress dysregulates the Hippo/YAP/14-3-3η pathway and induces mitochondrial damage in basolateral amygdala in a mouse model of depression.
Zhao Y; Chen Y; Guo C; Li P; Cheng Z; Zheng L; Sha B; Xu H; Su X; Wang Y
Theranostics; 2024; 14(9):3653-3673. PubMed ID: 38948066
[No Abstract] [Full Text] [Related]
76. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
77. Inactivation of Lats1 and Lats2 highlights the role of hippo pathway effector YAP in larynx and vocal fold epithelium morphogenesis.
Mohad V; Lungova V; Verheyden J; Thibeault SL
Dev Biol; 2021 May; 473():33-49. PubMed ID: 33515576
[TBL] [Abstract][Full Text] [Related]
78. Arterial Wall Stress Induces Phenotypic Switching of Arterial Smooth Muscle Cells in Vascular Remodeling by Activating the YAP/TAZ Signaling Pathway.
Wang Y; Cao W; Cui J; Yu Y; Zhao Y; Shi J; Wu J; Xia Z; Yu B; Liu J
Cell Physiol Biochem; 2018; 51(2):842-853. PubMed ID: 30466081
[TBL] [Abstract][Full Text] [Related]
79. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
80. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein.
DeRan M; Yang J; Shen CH; Peters EC; Fitamant J; Chan P; Hsieh M; Zhu S; Asara JM; Zheng B; Bardeesy N; Liu J; Wu X
Cell Rep; 2014 Oct; 9(2):495-503. PubMed ID: 25373897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
